Table 2.
Overall survival of the subgroups
| Group | Before PSM (n=604) |
After PSM (n=328) |
||
|---|---|---|---|---|
| MS (mo) | p-value | MS (mo) | p-value | |
| All cohort | ||||
| Chemotherapy | 15.2 | < 0.001 | 12.0 | 0.001 |
| BSC | 7.0 | 7.5 | ||
| Total | 12.1 | 9.6 | ||
| Locally advanced | ||||
| Chemotherapy | 28.0 | 0.010 | 16.7 | 0.490 |
| BSC | 13.4 | 13.4 | ||
| Total | 23.4 | 14.8 | ||
| Metastatic | ||||
| Chemotherapy | 12.7 | < 0.001 | 11.1 | < 0.001 |
| BSC | 6.2 | 6.3 | ||
| Total | 9.6 | 8.3 | ||
| ECOG 0-1 | ||||
| Chemotherapy | 17.0 | < 0.001 | 13.7 | 0.001 |
| BSC | 8.8 | 8.4 | ||
| Total | 14.2 | 11.3 | ||
| ECOG 2 | ||||
| Chemotherapy | 8.4 | 0.603 | 8.4 | 0.568 |
| BSC | 6.1 | 6.3 | ||
| Total | 6.6 | 6.6 | ||
| CA 19-9 ≤ 100 IU/mL | ||||
| Chemotherapy | 19.8 | 0.001 | 12.7 | 0.330 |
| BSC | 10.6 | 10.6 | ||
| Total | 16.2 | 12.3 | ||
| CA 19-9 > 100 IU/mL | ||||
| Chemotherapy | 11.8 | < 0.001 | 10.9 | 0.001 |
| BSC | 6.0 | 6.0 | ||
| Total | 9.1 | 8.2 | ||
| CEA ≤ 3.4 ng/mL | ||||
| Chemotherapy | 20.9 | 0.007 | 17.1 | 0.052 |
| BSC | 11.5 | 10.6 | ||
| Total | 17.8 | 12.3 | ||
| CEA > 3.4 ng/mL | ||||
| Chemotherapy | 10.2 | < 0.001 | 9.6 | 0.037 |
| BSC | 4.9 | 5.1 | ||
| Total | 8.2 | 6.7 | ||
| Male | ||||
| Chemotherapy | 14.7 | < 0.001 | 12.8 | 0.001 |
| BSC | 8.2 | 8.3 | ||
| Total | 12.0 | 10.3 | ||
| Female | ||||
| Chemotherapy | 16.5 | < 0.001 | 11.3 | 0.223 |
| BSC | 6.0 | 6.0 | ||
| Total | 12.4 | 8.6 | ||
PSM, propensity score matched; MS, median survival; BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen.